Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com -- Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) stock jumped 9.5% in Monday premarket trading after the company reported promising efficacy data for its cancer treatment CRB-701 in multiple tumor types.
The company presented data from its Phase 1/2 clinical study at the European Society for Medical Oncology Congress showing strong response rates in patients with head and neck squamous cell carcinoma (HNSCC), cervical cancer, and urothelial tumors. At the 3.6 mg/kg dose, CRB-701 demonstrated objective response rates of 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in urothelial cancer patients.
The study included 167 patients, with 122 evaluable for efficacy. Patients were heavily pretreated with a median of 3 prior lines of therapy. The drug showed activity regardless of biomarker status, including Nectin-4 expression, HPV status, or PD(L)-1 status.
CRB-701 also demonstrated a favorable safety profile with no dose-limiting toxicities during dose escalation. The most common treatment-related adverse events included dysgeusia (18.6%), anemia (21.0%), fatigue (21.6%), alopecia (24.0%), and keratitis (32.3%). Grade 3 treatment-related adverse events occurred in 18% of patients, with no grade 4 or 5 events reported.
Piper Sandler analyst Biren Amin raised the price target on Corbus Pharmaceuticals (NASDAQ:CRBP) to $51.00 (from $35.00) while maintaining an Overweight rating. The analyst said, "CRBP’s CRB-701 (Nectin-4 MMAE ADC) continues to look meaningfully active in heavily pre-treated HNSCC and cervical cancers (median of 3 prior lines) in its Phase 1/2 ESMO update, with ORR of 48% (10/21) in HNSCC and 38% (6/16) in cervical at the 3.6 mg/ kg dose – meaningfully higher than the bar set by Merus’ petosemtamab in HNSCC (36% ORR) and Tivdak in cervical (ORR of 18%)."
Corbus plans to meet with the FDA this year to review the data and expects to initiate registrational studies by mid-2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.